Skip to main content

ORIGINAL RESEARCH article

Front. Neurosci.

Sec. Neuropharmacology

Volume 19 - 2025 | doi: 10.3389/fnins.2025.1513135

This article is part of the Research Topic Neuropharmacological Intervention for Severe Mental Illness and Suicide Prevention View all 10 articles

Purinergic receptor antagonism reduces interictal discharges and rescues cognitive function in a mouse model of temporal lobe epilepsy

Provisionally accepted
  • 1 Pontificia Universidad Católica de Chile, Santiago, Chile
  • 2 Achucarro Basque Center for Neuroscience, Leioa, Spain

The final, formatted version of the article will be published soon.

    Epilepsy is one of the most prevalent neurological disorders globally. Current treatments mainly target neuronal activity, often overlooking the involvement of astrocytes and microglia in epilepsy's pathophysiology. Here, we explored the impact of purinergic receptors, predominantly found in glial tissue, on epileptiform activity. We used TNP-ATP, a potent purinergic receptor antagonist, and conducted experiments using a mouse model of mesial temporal lobe epilepsy to examine behavioral performance and neural activity patterns. Our findings reveal that although TNP-ATP treatment did not significantly impact motor function or anxiety levels, it reduced both the amplitude and rate of hippocampal interictal discharges. Such reduction also affected the synchrony of associated neuronal spiking. Additionally, cognitive function, particularly hippocampus-dependent spatial memory and prefrontal cortex-dependent executive control, were partially restored. Moreover, neuronal recordings showed increased phase coherence between the hippocampus and prefrontal cortex for both slow (theta) and fast (gamma) oscillations in treated animals, indicating strengthened neural coordination between cortical regions upon purinergic receptor antagonism. These results underscore the potential role of purinergic receptor antagonists in improving behavioural and cognitive performance in epilepsy, providing novel insight into the use of these pharmacological agents as a therapeutic approach.

    Keywords: purinergic receptor, Temporal Lobe Epilepsy, Interictal discharges, cognitive dysfunction, cortical oscillation

    Received: 17 Oct 2024; Accepted: 19 Feb 2025.

    Copyright: © 2025 Espinosa, Martin-Suarez, Lara-Vasquez, Montero, Muro- García, Fernandez, Encinas-Pérez and Fuentealba. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Pablo Fuentealba, Pontificia Universidad Católica de Chile, Santiago, Chile

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

    Research integrity at Frontiers

    Man ultramarathon runner in the mountains he trains at sunset

    94% of researchers rate our articles as excellent or good

    Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


    Find out more